SCHEMBL24175860

SCHEMBL24175860

COc1ccc(S(=O)(=O)/N=C/c2c(OC)ccc3ccccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.58
▸ HPGD P15428 1/20 0.58
▸ ALDH1A1 P00352 5/20 0.52
▸ LMNA P02545 3/20 0.50
▸ MEN1 O00255 5/20 0.48
▸ KMT2A Q03164 5/20 0.48
▸ MAPT P10636 4/20 0.48
▸ GAA P10253 3/20 0.48
▸ TDP1 Q9NUW8 3/20 0.48
▸ RRM1 P23921 1/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ RECQL P46063 1/20 0.46
▸ TUBB4A P04350 2/20 0.45
▸ TUBB P07437 2/20 0.45
▸ TUBA3C P0DPH7 2/20 0.45
▸ TUBA1B P68363 2/20 0.45
▸ TUBA4A P68366 2/20 0.45
▸ TUBB4B P68371 2/20 0.45
▸ TUBB3 Q13509 2/20 0.45
▸ TUBB2A Q13885 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24175847 0.90 KDM4E (0.58) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL26973856 0.88 KDM4E (0.57) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175864 0.88 KDM4E (0.57) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175867 0.88 KDM4E (0.60) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL26973691 0.87 ALDH1A1 (0.56) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175863 0.86 KDM4E (0.54) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175857 0.86 MAPT (0.67) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175862 0.85 MEN1 (0.57) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL24175865 0.83 KDM4E (0.53) KDM4EHPGDALDH1A1LMNAMEN1
SCHEMBL26973857 0.80 MEN1 (0.59) KDM4EHPGDALDH1A1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858879-B2 PARG inhibitors and method of use thereof CITY OF HOPE (US) 2024-01-02 — — US disclosed
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF CITY OF HOPE 2022-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002231-A1 PARG INHIBITORS AND METHOD OF USE THEREOF PARG, PARP12, PARP15 KDM4E 1170/4885HPGD 152/4885ALDH1A1 1104/4885
US-11858879-B2 PARG inhibitors and method of use thereof PARG, PARP12, PARP15 KDM4E 1170/4885HPGD 152/4885ALDH1A1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback